Actively Recruiting
Optimizing Ivonescimab Dose with PlatinumEtoposide Chemotherapy for Treating Extensive-Stage Small Cell Lung Cancer
Led by PrECOG, LLC. · Updated on 2026-08-28
60
Participants Needed
13
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ivonescimab, a bispecific antibody, in combination with carboplatin and etoposide chemotherapy for adults with Extensive Stage Small Cell Lung Cancer ES-SCLC who have not received prior treatment. The study is a randomized, open-label Phase II trial that aims to determine the best dose of ivonescimab for this patient population and assess its safety and overall response rate compared to previous studies in a different population. Participants will be randomly assigned to receive either ivonescimab 10 mgkg or 20 mgkg along with carboplatin and etoposide every 21 days for four cycles during the induction phase. After induction, participants will continue maintenance therapy with ivonescimab at the same dose every 21 days until disease progression, unacceptable side effects, or withdrawal, for up to 24 months from the first induction dose. During the study, participants will undergo tumor tissue collection at baseline for research purposes and regular blood sampling to monitor ivonescimab levels and immune responses. Researchers will evaluate treatment effects by measuring the overall response rate, treatment-related toxicity, progression-free survival, overall survival, disease control rate, and duration of response or stable disease. Treatment will be closely monitored for side effects, and participation can last up to several years depending on treatment duration and follow-up.
CONDITIONS
Brief Title
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Research Team
R
Rucha Shah, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here